Hepatitis B Virus and the Opioid Crisis

Similar documents
Targeted Outreach & Other Strategies for Increasing HCV Testing

HIV Surveillance in Urban and Nonurban Areas. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention

Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges

National Viral Hepatitis Action Plan Priority Populations Approach

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

CDC s Response to the Viral Hepatitis/Opioid Syndemic

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

Trends in HIV Incidence and Prevalence in the United States

The Syndemics of HIV, Hepatitis, and Overdose

Get Hip to Hep: Partnerships for Prevention

Promoting hepatitis B vaccination

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB. Prevention: NCHHSTP. Division of Viral Hepatitis

Hepatitis A and B outbreaks in Massachusetts,

How does HBV affect the liver?

Prevention of and Immunisation against Hepatitis B and C

Mortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention

Prevention of and Immunisation against Hepatitis B and C

NIDA Responds to the Syndemic of Opioids, Viral Hepatitis and HIV. Wilson M. Compton, M.D., M.P.E. Deputy Director, National Institute on Drug Abuse

Alabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs

Integrating Hepatitis Services into HIV Programs: The Local Health Department Perspective

5/2/2016. Dr Brooks has no relevant financial affiliations to disclose. (Update 04/15/16) Learning Objectives

Strategies to Address HCV

HIV/AIDS Surveillance Technical Notes

Prevention of and Immunisation against Hepatitis B and C

Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Opportunities For Hepatitis C Modalities in Substance Use Treatment Settings

San Francisco Department of Public Health Program Collaboration and Service Integration Surveillance Baseline Assessment

Hepatitis Case Investigation

Healthcare-Related Outbreaks of Hepatitis B and C in the United States

Estimates of New HIV Infections in the United States

Communicable Diseases

Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis

Is Elimination of Hepatitis C Possible?

DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland

Viral Hepatitis in the U.S.: Federal Partner Update

Mortality Slide Series. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention

HIV Testing Survey, 2002

HIV Prevention Service Provider Survey 2014

Estimates of New HIV Infections in the United States

State of Alabama HIV Surveillance 2014 Annual Report

HEPATITIS C SURVEILLANCE IN NYC AN OVERVIEW OF PROJECTS

Protecting and Promoting Health and Equity

Missouri Statewide Integrated HIV Prevention and Care Plan, including the Statewide Coordinated Statement of Need, CY

Welcome to Your Reading Assignment

Hepatitis B and Hepatitis B Vaccine

HIV/AIDS Epidemiology in Alameda County: State of the County Report

Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences

Hepatitis C in Massachusetts Epidemiology and Public Health Response

Patient-Centered Hepatitis C Virus (HCV) Care Via Telemedicine for Individuals on Opiate Agonist Treatment Marija Zeremski, PhD

Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago

Toronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action

Harm Reduction in Nigeria

Surveillance for Hepatitis C Among Youth in NYC. Kate Prussing Harlem Hep C Task Force Meeting, June 4, 2014

Glossary of Terms. Commercial Sex Worker: Self-reported as having received money, drugs or favors in exchange for sex.

Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)

STD, HIV and Hepatitis C 2017 Data Release. April 24,2018

HIV & HCV in TN: State of the State

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

SURVEILLANCE, REPORTING AND CONTROL OF VACCINE-PREVENTABLE DISEASES: WORKING TOGETHER TO CONTROL THE SPREAD

Health Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis in the United States

Registration.

Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States

Hepatitis C Best Practice Guidelines For Local Health Departments

Integrating Hepatitis Services into HIV Programs: Working Together to Meet Community Needs

Drug Use, Harm Reduction, and HIP

Adult Immunization Rates

Viral Hepatitis. WHO Regional Office for Europe July 2013

State of Alabama HIV Surveillance 2013 Annual Report Finalized

Miami-Dade County HIV/AIDS Epidemiological Data. July 8, 2010

PREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County

Outline. Successful Integration of Hepatitis Vaccination Services into Programs for High-Risk Adults An Update of State-Based Programs

Vaccination Policy. Background: Meningococcal Disease on Campus

Changing Patters of HIV Epidemiology United States

Additional North Carolina Projects

High Impact Prevention: Science, Practice, and the Future of HIV

HIV and AIDS in the United States

Syringe Exchange An Intervention that Works to Control the Spread of Hepatitis C and HIV. Health Department

Hepatitis STARS Program. Geri Brown, M.D. Associate Professor Department of Internal Medicine October 4, 2003

MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations

HIV Viral Suppression, 37 States and the District of Columbia, 2014

Signs of success latest national NESI data?

Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm

patients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:

HEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017

INTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT

Hepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016

Syringe Exchange Programs December 2005

NationalHepatitisCPrevention Strategy

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

Summary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017

Setting the Context: Understanding the Numbers, Vulnerable Populations and Federal Public Health Policy

Ontario Harm Reduction Conference April 30 to May 2, 2017 Toronto, Ontario

AIDS Cases by Exposure Category. Top 10 AIDS Cases by State/Territory. State HIV/AIDS Data. International Statistics

HIV/AIDS EPIDEMIOLOGY. Rachel Rivera, MD Assistant Professor Infectious Diseases UT Southwestern Medical Center November 14, 2014

Illustrating HIV/AIDS in the United States Update

Transcription:

Hepatitis B Virus and the Opioid Crisis Alice Asher, RN, Ph.D. Epidemiology and Surveillance Branch Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention

*Disclaimer The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Background PWID are at high risk of transmission of blood borne viruses, including hepatitis B virus (HBV) The opioid epidemic and increasing rates of injection drug use are propelling infections in certain populations PWID are often hard-to-reach and difficult to follow to series completion; novel methods to engage this population are critical to success

Rising trends in opiate misuse SAMHSA - Treatment Episode Data Set (TEDS-A)

Reported acute HBV cases 2001-2016 9,000 8,000 Number of cases 7,000 6,000 5,000 4,000 3,000 2,000 1,000 0 2001 2004 2007 Year 2010 2013 2016 Source: National Notifiable Diseases Surveillance System (NNDSS)

Incidence of acute HBV, by age group 2001-2016 Reported cases/100,000 population 6 5 4 3 2 1 0-19 yrs 20-29 yrs 30-39 yrs 40-49 yrs 50-59 yrs 60+ yrs 0 2001 2004 2007 Year 2010 2013 2016 Source: National Notifiable Diseases Surveillance System (NNDSS)

Incidence of acute HBV, by race/ethnicity 2001-2016 Reported cases/100,000 population 6 5 4 3 2 1 0 2001 2004 2007 2010 American Indian/Alaska Native Asian/Pacific Islander Black, Non-Hispanic White, Non-Hispanic Hispanic 2013 2016 Year Source: National Notifiable Diseases Surveillance System (NNDSS)

Injection drug use and acute HBV - 2016 48% of reported cases provide any risk data 22% with any information on risk have risk factors identified Of those, 53% report a history of injection drug use In 2015, 43% of identified risk factors were associated with IDU Source: National Notifiable Diseases Surveillance System (NNDSS)

Characteristics of persons with acute hepatitis B virus infection (N = 298), Florida, 2011 2018

Increases in HBV infection among PWID: Kentucky, West Virginia, Tennessee Harris, et al, MMWR, 2016

Increases in HBV infection among PWID: Kentucky, West Virginia, Tennessee Harris, et al, MMWR, 2016

Increases in HCV Incidence - United States Reported cases/100,000 population 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 Male Female Rate Per 100,000 1.4 1.2 1.0 0.8 0.6 0.4 0.2 Metropolitan Nonmetropolitan 0.0 2000 2003 2006 Year 2009 2012 2015-2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Year of Report 1:1 male: female ratio, predominantly white Highest incidence- 20-29 years, non-urban areas Suryaprasad, CID 2014, Zibbell MMWR 2015, CDC unpublished data

Injection drug use and HBV Highly efficient. Can be spread through drug paraphernalia, not just needles and syringes Long survival period on inanimate objects One drop of blood with HBV, HCV and HIV 30% chance of getting HBV 1.8% chance of getting HCV.03% chance of getting HIV Hagan H, et al, 2010; CDC 2016

Adults Recommended to Receive HBV Vaccination Persons at risk for infection by sexual exposure Sex partners of hepatitis B virus (HBV)-infected persons Sexually active persons not in a long-term, mutually monogamous relationship Persons seeking evaluation or treatment for a sexually transmitted disease Men who have sex with men Persons at risk for infection by percutaneous/mucosal exposure to blood Current or recent injection-drug users Household contacts of HBV-infected persons Residents and staff of facilities for developmentally disabled persons Healthcare and public safety workers Persons with end-stage renal disease Persons with diabetes Others International travelers to regions with high/intermediate HBV infection Persons with chronic liver disease Persons with HIV infection All other persons seeking protection from HBV infection Mast et al, MMWR 2006. 14 of 23

Settings in which HBV Vaccination is Recommended for All Adults Sexually transmitted disease treatment facilities HIV testing and treatment facilities Facilities providing drug-abuse treatment and prevention services Health-care settings targeting services to injection-drug users Correctional facilities Health-care settings targeting services to men who have sex with men Chronic hemodialysis facilities and end-stage renal disease programs Institutions and nonresidential day are facilities for developmentally disabled persons Mast et al, MMWR 2006. 15 of 23

Missed Opportunities for Adult Hepatitis B Vaccination Of all persons with reported acute hepatitis B: 37% reported prior treatment for an STD 29% reported prior incarceration 56% had been treated for an STD and/or incarcerated in a prison or jail prior to their illness Goldstein et al., 2002

Successful series completion Engagement with social services/ability to rely on outreach workers Longer injecting career History of HIV and HCV testing Utilization of syringe service programs Financial incentives Lum et al, 2003; Altice et al 2005; Bowman et al 2014

Hepatitis B Vaccine HBV vaccine administered intramuscularly produces a protective antibody response in approximately 30%-55% of healthy adults aged <40 years after the first dose 75% after the second dose, and >90% after the third dose. Even if compliance with vaccination series not perfect, one dose better than none, 2 better than 1 Concerns about series completion is not a reason not to initiate first dose INITIATE VACCINE AT EARLIEST CONTACT

Accelerated vaccination schedule WHO guidelines suggest utilizing Twinrix accelerated schedule to improve series completion for PWID Standard schedule Accelerated schedule Dose Day Day #1 0 0 #2 30 7 #3 6 months 21-28 On accelerated schedule, provide booster dose at 1 year World Health Organization, 2012

Conclusions HBV related to IDU is increasing Younger age, mostly white population, similar to that affected by increasing HCV infection Despite being a highly mobile, hard-to-reach population that often is reluctant to access medical care, PWID can successfully complete a 3-dose series for HBV vaccination Targeted outreach campaigns, utilizing registries and leveraging other organizations improves series completion is important These methods offer a successful recruiting and retention framework for PWID involvement in other health care initiatives and for community based organizations working with this population.

Thank you! Questions: Alice Asher AAsher@cdc.gov